Results demonstrated that Lymphoseek identified sentinel lymph nodes (SLNs) in subjects with squamous cell carcinoma of the head or neck with a false negative rate (FNR) of 2.56 percent, whereas sulfur colloid demonstrated an FNR of 10 percent (p = 0.0006

Bionomics Ltd., of Thebarton, Australia, said it completed enrollment in its Phase II trial testing the combination of vascular disrupting agent BNC105 plus mTOR inhibitor Afinitor (everolimus, Novartis AG) in patients with advanced renal cell carcinoma

AGS-003 is being evaluated in combination with standard surgery followed by targeted drug therapy in the study to determine its potential to extend overall survival in newly diagnosed, unfavorable risk metastatic renal cell carcinoma patients

Exelixis Inc., of South San Francisco, started METEOR, a Phase III pivotal trial comparing cabozantinib to everolimus (Afinitor, Novartis) in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor

Lpath Inc., of San Diego, began dosing in a Phase IIa trial of Asonep for renal cell carcinoma in patients that have failed standard VEGF- or mTOR-targeted treatments

The study, which was published in the May 2013 issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests

In a six-patient trial assessing synergy between CRLX101 and Avastin in renal cell carcinoma, the drug combination was well tolerated without dose-limiting toxicities...Results of the pre-planned interim analysis showed that Lymphoseek met the primary efficacy endpoint of accurately identifying sentinel lymph nodes in subjects with squamous cell carcinoma of the head or in the mouth, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck

single-arm Phase II trial (REO 021) of intravenous Reolysin in combination with carboplatin and paclitaxel met the primary statistical endpoint of objective tumor response rate in squamous cell carcinoma of the lung (SCCLC

Argos Therapeutics Inc., of Durham, N.C., said it validated the durability of the immune response for metastatic renal cell carcinoma patients treated with AGS-003

Argos Therapeutics Inc., of Durham, N.C., reported updated results from its Phase II study of AGS-003, its most advanced product candidate for the treatment of metastatic renal cell carcinoma (mRCC

Oncolytics Biotech Inc., of Calgary, Alberta, said that in a Phase II trial of Reolysin with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lung, 95 percent of evaluable patients (19 out of 20) had overall tumor shrinkage

Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing dalantercept (ACE-041), an angiogenesis inhibitor designed to target the activin receptor-like kinase pathway, in combination with Inlyta (axitinib, Pfizer Inc.), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma

standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma

The Phase III trial of Lymphoseek (technetium Tc 99m tilmanocept) for injection, an intraoperative lymphatic mapping agent, is designed to demonstrate the performance of Lymphoseek in identifying sentinel lymph nodes in subjects with squamous cell carcinoma on the head or in the mouth

OncoSec Medical Inc., of San Diego, reported that ImmunoPulse, delivered by electroporation, may give increased levels of interleukin-12 in the microenvironment of tumors in Merkel cell carcinoma

OncoSec Medical Inc., of San Diego, reported interim results from a Phase IV trial of NeoPulse in skin cancer at the World Meeting of Interdisciplinary Melanoma and Skin Care Centres and EADO Congress in Barcelona, Spain, showing a complete response greater than 90 percent in basal cell carcinoma patients and 70 percent in squamous cell carcinoma patients at six months

Immatics biotechnologies GmbH, of Tuebingen, Germany, completed patient recruitment into the pivotal Phase III trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC

The trial enrolled Merkel cell carcinoma patients

Pfizer Inc., of New York, said a Phase III study of Inlyta (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS) vs. Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG) in treatment-naïve patients with advanced renal cell carcinoma